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Urinary protein excretion rate is the best independent predictor of
ESRF in non-diabetic proteinuric chronic nephropathies. We investigated
the predictors of the rate of glomerular filtration rate decline (DGFR) and
progression to end-stage renal failure (ESRF) in the 352 patients with
proteinuric non-diabetic chronic nephropathies [urinary protein excretion
rate (UProt) $ 1 g/24 hr, creatinine clearance 20 to 70 ml/min/1.73 m
2]
enrolled in the Ramipril Efficacy In Nephropathy (REIN) study. Overall
the GFR declined linearly by 0.46 6 0.05 ml/min/1.73 m2/month (mean
rate 6 SEM) over a median follow-up of 23 months (range 3 to 64 months),
and progression to ESRF was 17.3%. Using multivariate analysis, higher
UProt and mean arterial pressure (MAP) independently correlated with a
faster DGFR (P 5 0.0001 and P 5 0.0002, respectively) and progression to
ESRF (P 5 0.0001 and P 5 0.003, respectively). Mean UProt and systolic
blood pressure during follow-up were the only time-dependent covariates
that significantly correlated with DGFR (P 5 0.005 and P 5 0.003,
respectively) and ESRF (P 5 0.006 and P 5 0.0001, respectively). After
stratification for baseline UProt, patients in the lowest tertile (UProt , 1.9
g/24 hr) had the slowest DGFR (0.16 6 0.07 ml/min/1.73 m2/month) and
progression to ESRF (4.3%) as compared with patients in the middle
tertile (UProt 2.0 to 3.8 g/24 hr; DGFR, 0.55 6 0.09 ml/min/1.73 m
2/month,
P 5 0.0002; ESRF, 15.3%, P 5 0.0001) and in the highest tertile (UProt 3.9
to 18.8 g/24 hr; DGFR, 0.70 6 0.11 ml/min/1.73 m2/month, P 5 0.0001;
ESRF, 32.5%, P 5 0.0001). Both DGFR (P 5 0.01) and progression to
ESRF (P 5 0.01) significantly differed even between the middle and the
highest tertiles. On the contrary, stratification in tertiles of baseline MAP
failed to segregate subgroups of patients into different risk levels. Patients
with the highest proteinuria and blood pressure were those with the fastest
progression (DGFR, 0.91 6 0.23; ESRF 34.7%). Of interest, at each level
of baseline MAP, a higher proteinuria was associated with a faster DGFR
and progression to ESRF. On the other hand, at each level of proteinuria,
a faster DGFR was associated with MAP only in the highest tertile (. 112
mm Hg) and the risk of ESRF was independent of the MAP. Thus, in
chronic nephropathies proteinuria is the best independent predictor of
both disease progression and ESRF. Arterial hypertension may contribute
to the acceleration of renal injury associated with enhanced traffic of
plasma proteins. Antihypertensive drugs that most effectively limit protein
traffic at comparable levels of blood pressure are those that most
effectively slow disease progression and delay or prevent ESRF in
proteinuric chronic nephropathies.
After a given insult most experimental and human renal
diseases progress to terminal renal failure even independently of
the event(s) responsible for the initial lesion [1, 2]. Among the
several theories on the pathophysiology of progressive nephrop-
athies [1–4], the most convincing one [1, 2] implies that the initial
reduction in nephron number imposes with time a progressive
damage to the remaining ones suffering the consequences of
adaptive increases in glomerular pressure and flow. Enhanced
pressure within glomerular capillaries–which originally serves to
maintain ultrafiltration despite fewer nephrons–is usually fol-
lowed by enhanced trans-glomerular ultrafiltration of plasma
proteins that above certain values are then excreted in the urine
[5–7]. While in the past proteinuria was mostly regarded as a
marker of the severity of the underlying disease, today the results
of many studies [4, 8–10] converge to indicate that proteins
filtered through the glomerular capillary have an intrinsic renal
toxicity that would possibly contribute to the progression of the
lesions [reviewed in 11, 12]. In particular, excess of urinary
proteins correlated with both a faster GFR decline and progres-
sion to ESRF in many experimental and human studies [13–16],
and it now emerges as a predictor of renal disease progression in
insulin dependent diabetics [14].
Drug therapy limiting the rate of GFR decline over time and
thus the progression to ESRF has become increasingly more
effective. In particular, angiotensin converting enzyme (ACE)
inhibitors, which in addition to effectively decreasing arterial
blood pressure ameliorate glomerular barrier size-selectivity and
reduce glomerular protein ultrafiltration and proteinuria in hu-
man diabetic nephropathy, have proven to be more effective than
other antihypertensives such as beta blockers and diuretics [17,
18]. This suggests that their superior renoprotective properties
could be related to their specific effect on glomerular protein
traffic [15, 16, 19].
In the present study, we prospectively analyzed the impact of
baseline and time-dependent parameters on the rate of GFR
decline and risk of progression to ESRF in a large cohort of
patients with nondiabetic renal disease and clinical proteinuria
who were enrolled in the Ramipril Efficacy in Nephropathy
(REIN) study. This trial was designed to formally address the
hypothesis that glomerular protein traffic and its modification by
an ACE inhibitor influenced the progression of chronic renal
disease [20, 21]. To this purpose, the rate of GFR decline and the
risk of progression to ESRF were studied in two groups of
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patients randomly allocated to the same degree of blood pressure
control (diastolic blood pressure , 90 mm Hg) achieved with the
ACE inhibitor Ramipril or with a placebo, plus non-ACE inhib-
itor antihypertensives as appropriate. According to the baseline
urinary protein excretion rate, patients were separated a priori
into two groups (Stratum 1, 1.0 to 2.9 g/24 hr; Stratum 2, $ 3 g/24
hr), to evaluate the impact of protein traffic on progression.
According to the Declaration of Helsinki, all patients provided
signed, written informed consent before study entry.
METHODS
Study design
A detailed description of the REIN study design and results has
been published elsewhere [20, 21]. The active treatment and
placebo were supplied by Hoechst AG (Frankfurt am Main,
Germany). Study participants were patients of either sex, between
18 and 70 years, with proteinuric chronic nephropathy, with or
without hypertension. Chronic nephropathy was defined as creat-
inine clearance in the range 20 to 70 ml/min/1.73 m2 as a mean of
three monthly consecutive measurements, with a creatinine clear-
ance variation of less than 30% in the three months prior to study
entry (in order to exclude patients with acute or rapidly progres-
sive renal insufficiency). Persistent proteinuria was defined as a
urinary protein excretion . 1 g/24 hr over at least three months
with no evidence of urinary tract infection or overt heart failure
(NYHA class III-IV). Exclusion criteria were: treatment with
corticosteroids, non-steroidal anti-inflammatory drugs, or immu-
nosuppressive drugs; acute myocardial infarction or cerebrovas-
cular accident in the previous six months; severe uncontrolled
hypertension (diastolic blood pressure $ 115 and/or systolic blood
pressure $ 220 mm Hg); evidence or suspicion of renovascular
disease, obstructive uropathy, insulin-dependent diabetes melli-
tus, collagen disease, cancer, higher serum aminotransferase
concentrations, or chronic cough; drug or alcohol abuse; preg-
nancy; breast feeding; and ineffective contraception.
According to baseline urinary protein excretion rate (estimated
by the mean of two consecutive measurements two weeks apart),
before randomization and within each clinical center, patients
Table 1. Overall and per tertile of 24-hour urinary protein excretion rate baseline characteristics of 352 patients with chronic renal insufficiency
and clinical proteinuria
Tertiles of baseline proteinuria
OverallLowest Middle Highest
Patients N 117 118 117 352
Urinary protein excretion g/24 hr
Range 0.5–1.9 2.0–3.8 3.9–18.8 0.5–18.8
Mean 6 SD 1.25 6 0.40 2.83 6 0.54a 6.16 6 2.43a,b 3.41 6 2.50
Clinical parameters
Age years 50.3 6 13.2 48.0 6 13.9 49.7 6 13.8 49.3 6 13.6
Male sex % 75.2 72.9 81.2 76.4
Systolic BP mm Hg 139.2 6 18.1 144.2 6 18.2 148.5 6 17.8a,f 144.0 6 18.4
Diastolic BP mm Hg 86.9 6 11.9 89.2 6 10.8 90.3 6 11.4 88.4 6 11.4
Mean BP mm Hg 104.3 6 12.8 107.5 6 12.3 109.7 6 12.0c 107.2 6 12.5
Diagnosis
Glomerular disease % 29.9 47.5e 48.7e 42.0
APKD or Interstitial nephritis % 7.7 5.9 4.3 6.0
Other or unknown % 62.4 46.6 47.0 52.0
Laboratory parameters
GFR ml/min/1.73 m2 46.8 6 18.6 43.7 6 18.4 38.7 6 17.9c,f 43.2 6 18.5
Creatinine clearance ml/min/1.73 m2 50.8 6 19.9 50.7 6 21.8 46.4 6 21.7 49.3 6 21.2
Serum creatinine mg/dl 2.0 6 0.8 2.1 6 0.9 2.5 6 1.1a,d 2.2 6 1.0
Total cholesterol mg/dl 229.6 6 48.7 237.2 6 57.0 264.1 6 74.7c,d 243.8 6 62.8
Triglycerides mg/dl 167.9 6 124.1 191.2 6 160.3 209.7 6 134.8c,f 189.6 6 141.3
Uric acid mg/dl 6.7 6 1.5 6.9 6 1.7 6.8 6 1.5 6.8 6 1.6
Serum potassium mEq/liter 4.4 6 0.6 4.4 6 0.6 4.5 6 0.6 4.4 6 0.6
a P 5 0.0001 vs. lowest
b P 5 0.0001 vs. middle
c P , 0.005 vs. lowest
d P , 0.005 vs. middle
e P , 0.05 vs. lowest
f P , 0.05 vs. middle
Table 2. Univariate analysis of the correlation between baseline
parameters, decline in glomerular filtration rate (DGFR) and
progression to end-stage renal failure (ESRF)
Baseline parameters
DGFR ESRF
r coefficient P value P value
Clinical parameters
Age 20.03 0.62 0.72
Sex 0.01 0.84 0.31
Systolic blood pressure 20.21 0.0002 0.001
Diastolic blood pressure 20.17 0.003 0.003
Mean blood pressure 20.21 0.0002 0.0002
Diagnosis 0.03 0.29 0.28
Laboratory parameters
Urinary protein excretion 20.22 0.0001 0.0001
GFR 20.044 0.46 0.0001
Creatinine clearance 0.13 0.02 0.0001
Serum creatinine 20.08 0.16 0.0001
Total cholesterol 20.048 0.41 0.23
Triglycerides 20.07 0.22 0.48
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were separated into two groups (Stratum 1, 1.0 to 2.9 g/24 hr;
Stratum 2, $ 3 g/24 hr) and were then randomly assigned 1.25 mg
capsules of Ramipril or of placebo (identical appearance) on a 1:1
basis within each stratum. The first dose of the study drugs, and
that of increment dosages (that is, 2.5 or 5.0 mg capsules of
Ramipril or placebo) were given in hospital and patients moni-
tored for four hours after ingestion. The study-drug dose was
increased every two weeks until “trough” diastolic blood pressure
(measured in the morning before study drug administration) was
reduced to under 90 mm Hg. Antihypertensive agents (but not
ACE inhibitors) were introduced (diuretics as first choice, cen-
trally acting sympatholytic agents and vasodilators–including di-
hydropiridinic calcium channel blockers–as second and third
choices, respectively) were introduced, and their doses adjusted to
achieve and maintain diastolic blood pressure under 90 mm Hg.
In patients already receiving antihypertensive agents, the study
drug dose was increased and the dose of the other antihyperten-
sive drugs progressively reduced to avoid symptomatic hypoten-
sion. In each patient, the broad aim was to adjust the dose of the
study drugs to achieve and maintain the target blood pressure with
the minimum dose of concomitant antihypertensive agents. An-
giotensin converting enzyme inhibitors or antagonists to angioten-
sin II receptor could not be added to the study drugs during the
study period. Each patient was examined by a physician at
baseline, every month during the first three months after random-
ization, and every three months thereafter. At each examination,
arterial blood pressure was measured with the patient in the
sitting position in the morning and before ingestion of the
antihypertensive drugs, and routine laboratory parameters, in-
cluding 24-hour urinary protein excretion rate, were evaluated. At
baseline, and one, three, and six months after randomization, and
every six months thereafter, patients had their GFR centrally
evaluated at the Mario Negri Institute for Pharmacological Re-
search (Bergamo, Italy) by the plasma clearance of nonradioactive
iohexol method [22]. This is a precise and reliable indicator of the
GFR that tightly correlates (r 5 0.892, P , 0.001) with the renal
clearance of inulin over a wide range of renal function [22].
Urinary protein excretion was measured by the biuret precipita-
tion method [23] in all participating centers in order to minimize
variation in protein measurement. The main objective of the trial
was to compare the effect of the two study treatments (Ramipril
vs. placebo) on the rate of GFR decline and on kidney survival, at
comparable level of blood pressure control.
Statistical analysis
Baseline and time-dependent covariates were evaluated in all
the 352 patients randomized in the REIN study. Linear, quadratic
and cubic time trends were analyzed by fitting orthogonal poly-
nomials to each subject and then by analysis of variance on
polynomial coefficients. Individual GFR declines were estimated
by the linear regression model (least squares method). Only
patients with at least three GFR evaluations (including baseline)
were considered to derive DGFR slopes.
Correlation analysis between baseline and time-dependent co-
variates and DGFR slopes was univariately carried out using
Pearson’s r correlation coefficient for continuous variables and
using point-biserial correlation coefficient for dicothomous vari-
ables [24]. Multivariate analysis was performed using multiple
linear regression [25]. The renal end-points, dialysis or transplan-
tation, were univariately and multivariately analyzed by Cox’s
proportional hazards model [26]. The role of treatment (Ramipril
or placebo) as time-dependent covariate was evaluated in all
patients who were on open treatment at the time of the present
report (that is, patients with baseline proteinuria $ 3 g/24 hr).
Three subgroups of patients (tertiles) were segregated a poste-
riori according to: (a) lowest, middle or highest baseline urinary
protein excretion rate; and (b) lowest, middle or highest baseline
mean arterial blood pressure. Comparisons between tertiles were
done using Wilcoxon test, rank-sum Fisher’s exact test or log-rank
test as appropriate. Data analyses were performed using the SAS
System, Release 6.12. Data were expressed as mean 6 SEM or as
a percentage, as appropriate. Statistical significance was set at 0.05
(two-tailed).
RESULTS
The baseline clinical and laboratory parameters of the 352
patients under evaluation are listed in Table 1. After linear
assessment, the individual slopes were found adequate to describe
the rate of GFR decline. The actual mean rate (6 SEM) of GFR
decline in the entire cohort was 0.46 6 0.05 ml/min/1.73 m2/month
(0.27 6 0.06 ml/min/1.73 m2/month in the 186 patients of Stratum
1 vs. 0.69 6 0.09 ml/min/1.73 m2/month in the 166 patients of
Stratum 2, P 5 0.0001). Among Stratum 2 patients, DGFR was
significantly lower in the Ramipril group than in the placebo
group (0.53 6 0.08 ml/min/1.73 ml/min/m2/month vs. 0.88 6 0.13
ml/min/1.73 m2/month, P 5 0.03) [21]. Over a mean follow-up of
23 months (range 3 to 64 months), the overall progression to
ESRF was 17.3% (6.4% vs. 29.9% in Stratum 1 and Stratum 2,
Fig. 1. Rate of glomerular filtration rate (GFR) decline per tertile of
baseline urinary protein excretion rate. DGFR for: lowest is 0.16 6 0.07;
middle is 0.55 6 0.09; highest is 0.70 6 0.11.
Table 3. Multivariate analysis of the correlation between baseline
parameters, decline in glomerular filtration rate (DGFR) and
progression to end-stage renal failure (ESRF)
Baseline parameters DGFR ESRF
Clinical parameters
Age 0.37 0.54
Sex 0.69 0.26
Mean blood pressure 0.0002 0.0037
Diagnosis 0.69 0.07
Laboratory parameters
Urinary protein excretion 0.0001 0.0001
GFR 0.08 0.0001
Total cholesterol 0.35 0.06
Triglycerides 0.87 0.54
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respectively, P 5 0.0001). Mean diastolic blood pressure during
follow-up was virtually identical in the two treatment groups
(88.2 6 0.9 mm Hg and 88.9 6 0.9 mm Hg in the Ramipril and
placebo groups, respectively). Since protocol guidelines to antihy-
pertensive therapy were the same for both strata, a comparable
level of blood pressure control between the two treatment groups
was also expected in Stratum 1 patients, who still were on the
double blind treatment [21]. Among baseline parameters listed in
Table 1, a higher baseline 24-hour urinary protein excretion rate
and MAP were the only variables found to significantly predict a
faster DGFR either at univariate or multivariate correlation
analysis (Tables 2 and 3). When ESRF was considered as outcome
variable, a higher 24-hour urinary protein excretion was the only
baseline parameter that had a highly significant predictive value
either at univariate or multivariate analysis (Tables 2 and 3).
Among time-dependent covariates, at univariate analysis the
mean systolic and diastolic blood pressures and 24-hour urinary
protein excretion rate measured during follow-up significantly
correlated with both DGFR (P 5 0.0001, P 5 0.001, and P 5
0.0016, respectively) and ESRF (P 5 0.0001, P 5 0.0117, and P 5
0.0001, respectively).
At multivariate analysis, the mean systolic blood pressure and
24-hour urinary protein excretion rate measured during follow-up
were the only time-dependent covariates that significantly corre-
lated with DGFR (P 5 0.005 and P 5 0.003, respectively) and
ESRF (P 5 0.006 and P 5 0.0001, respectively). As expected, the
mean GFR during follow-up significantly correlated with ESRF
(P 5 0.0001), but not with DGFR.
When the data of mean DGFR and progression to ESRF were
analyzed according to tertiles of baseline urinary protein excretion
and MAP, it emerged that urinary protein excretion, but not
MAP, could segregate patients with predictably different rates of
DGFR (Fig. 1 and Table 4) and ESRF (Fig. 2 and Table 4) into
three distinct populations. Patients with a non-nephrotic range
Fig. 2. Progression to end-stage renal failure per tertile of baseline urinary protein excretion rate. Symbols are: (F) lowest; () middle; (E) highest
tertile.
Table 4. Rate of glomerular filtration rate decline (DGFR) and progression to end-stage renal failure (ESRF) per tertile of baseline mean arterial
pressure in 352 patients with chronic renal insufficiency and clinical proteinuria
Tertiles of baseline mean arterial pressure
OverallLowest Middle Highest
Patients N 117 116 119 352
Mean arterial pressure mm Hg
Range 72.2–101.7 101.9–111.8 112.2–143.9 72.2–143.9
Mean 6 SD 94.0 6 6.4 106.8 6 3.0 120.9 6 7.7 107.3 6 12.6
Progression of renal disease
DGFR ml/min/month/1.73 m2 0.34 6 0.08 0.29 6 0.08 0.75 6 0.11a 0.46 6 0.05
ESRF N (%) 18 (15.4%) 16 (13.7%) 27 (22.9%)a 61 (17.3%)
a P , 0.005 vs. middle and highest
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baseline urinary protein excretion rate (lowest tertile) had a
DGFR close to the rate of GFR decline reported in previous
European series of insulin dependent diabetics with clinical
proteinuria [13, 17]. On the other hand, patients with higher
baseline urinary protein excretion rate had a faster DGFR, which
was maximal in the highest tertile (Fig. 1). In line with data on
DGFR, progression to ESRF was lowest in patients in the lowest
tertile and highest in patients in the highest tertile (Fig. 2).
Of interest, age, baseline creatinine clearance, and the preva-
lence of glomerular and nonglomerular diseases were comparable
in the three subgroups (Table 1). Baseline GFR and serum
creatinine concentration were comparable in the lowest and in the
middle tertiles, but were respectively lower and higher in the
highest tertile. Because of a priori stratification for two different
levels of baseline urinary protein excretion rate, the patient
distribution into the two study treatments was comparable in the
overall study population and within each tertile. Serum choles-
terol was higher in the highest and middle as compared with the
lowest tertile and was the only baseline parameter, in addition to
24-hour urinary protein excretion rate and MAP, which at multi-
variate analysis independently predicted ESRF, but not DGFR, in
the long term.
When tertiles of baseline proteinuria and MAP were consid-
ered together, nine subgroups of patients with different rates of
progression were identified (Tables 5 and 6, Figs. 3 and 4).
Patients with the highest proteinuria and blood pressure were
those with the fastest progression (DGFR, 0.91 6 0.23; kidney
survival, 65.3%) compared to those in the other subgroups. Of
interest, at each level of baseline MAP, a higher proteinuria was
associated with a faster DGFR and a higher risk of ESRF. On the
other hand, at each level of proteinuria, a faster DGFR was
associated only with a MAP in the highest tertile and the risk of
ESRF was independent of the level of MAP.
DISCUSSION
The results of the present study found that in proteinuric
nephropathies, independently of the nature of the underlying
disease, baseline urinary protein excretion rate is the best single
predictor of renal disease progression. In particular, the higher
the urinary protein excretion values, the faster the subsequent
decline in GFR and, even more important, the quicker the
progression to ESRF. Thus, patients with a baseline urinary
protein excretion rate , 1.9 g/24 hr had the lowest rate of GFR
decline and kidney failure (, 5%) over the subsequent three years
of follow-up. On the other hand, patients with nephrotic range
proteinuria (. 3.9 g/24 hr) lost more than 10 ml/min/1.73 m2 of
GFR per year and had a follow-up after three years where kidney
failure was . 30%. Thus, unlike higher arterial blood pressure,
higher baseline proteinuria was a strong predictor of a lower
kidney survival. These findings cannot be accounted for by specific
treatment effects, because before randomization in the REIN
study, patients were stratified into two levels of baseline urinary
protein excretion rate, which allowed for a well balanced alloca-
tion into the two study treatments within each tertile of protein-
uria.
Of interest, in the present study, the higher blood pressure
predicted a faster GFR decline and a lower kidney survival only
for a MAP above 112 mm Hg during the follow-up period. Thus,
at variance with urinary proteins, segregation in tertiles of base-
line MAP failed to identify three subgroups of patients with
predictably different renal disease progression. In addition, when
tertiles of baseline proteinuria and MAP were considered to-
gether, at each level of MAP, different degrees of proteinuria
persistently predicted different kidney outcomes. On the contrary,
at each level of proteinuria, the risk of progression to ESRF was
independent of baseline MAP and the rate of GFR decline was
increased only for a MAP above 112 mm Hg. Thus, in proteinuric
non-diabetic renal disease, MAP predicts GFR decline and kidney
survival less effectively than the 24-hour urinary protein excretion
rate. However, evidence that very high baseline blood pressure is
associated with a faster GFR decline suggests that uncontrolled
hypertension may contribute to the acceleration of renal injury
consequent to enhanced protein traffic through the glomerular
capillaries. This hypothesis is further corroborated by finding that
the mean follow-up systolic arterial blood pressure and 24-hour
urinary protein excretion rate both strongly and independently
correlated with the rate of GFR decline and with the risk of
progression to ESRF.
Abnormalities in lipid metabolism, which consistently parallel
the severity of proteinuria, may also play a role in the progression
of renal injury in glomerular diseases [27]. Actually, as expected,
in this study patients with higher baseline urinary proteins had
more dyslipidemia. However, using multivariate analysis, the
serum triglyceride concentration had no predictive value, and
serum cholesterol predicted a lower kidney survival but did not
correlate with the decline in GFR. In addition, neither serum
triglycerides nor serum cholesterol correlated with the rate of
GFR decline and progression to ESRF during the follow-up
Table 5. Rate of GFR decline per tertiles of base-line 24 hour urinary
protein excretion rate and mean arterial pressure (MAP) in 352
patients with chronic renal insufficiency and clinical proteinuria
Tertiles of
baseline MAP
Tertiles of baseline proteinuria
OverallLowest Middle Highest
Lowest 0.16 6 0.11 0.49 6 0.17 0.48 6 0.11a 0.34 6 0.08
Middle 0.09 6 0.12 0.31 6 0.10c 0.64 6 0.18b 0.29 6 0.08
Highest 0.41 6 0.11d 0.89 6 0.19e 0.91 6 0.23c 0.75 6 0.11
Overall 0.16 6 0.07 0.55 6 0.09 0.70 6 0.11 0.46 6 0.05
Abbreviations are: Prot., Proteinuria; MAP, mean arterial pressure.
a P , 0.01 vs. Lowest Prot.
b P , 0.0005 vs. Lowest Prot. and ,0.05 vs. Middle Prot.
c P , 0.05 vs. Lowest Prot.
d P , 0.05 vs. Lowest MAP, and ,0.01 vs. Middle MAP
e P , 0.05 vs. Lowest and Middle MAP
Table 6. Progression to end stage renal failure per tertiles of baseline
24-hour urinary protein excretion rate and mean arterial pressure in
352 patients with chronic renal insufficiency and clinical proteinuria
Tertiles of
baseline MAP
Tertiles of baseline proteinuria
OverallLowest Middle Highest
Lowest 2 (4.1%) 5 (13.2%) 11 (36.7%)a 18 (15.4%)
Middle 1 (2.9%) 5 (11.6%) 10 (26.3%)b 16 (13.6%)
Highest 2 (6.1%) 8 (23.5%) 17 (34.7%)c 27 (23.1%)
Overall 5 (4.3%) 18 (15.7%) 38 (32.5%) 61 (17.3%)
Abbreviations are: Prot., Proteinuria; MAP, mean arterial pressure.
a P , 0.0005 vs. Lowest Prot.
b P , 0.001 vs. Lowest Prot. and 50.01 vs. Middle Prot.
c P 5 0.001 vs. Lowest Prot.
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period, suggesting a limited independent role for dyslipidemia in
the progression of chronic renal disease.
Neither biases in patient randomization or in blood pressure
control accounted for the remarkable differences in renal disease
progression demonstrated for different levels of the baseline
urinary protein excretion rates. In addition, glomerular and
nonglomerular diseases were similarly represented in the three
tertiles, which renders it extremely unlikely that different renal
outcomes were actually dependent on different underlying renal
diseases, rather than on the degree of proteinuria. Consistent with
the above considerations were the multivariate analysis data
showing that baseline urinary protein excretion, but not the
underlying renal disease, predicted the risk of progression during
the subsequent follow-up. Along this same vein were the results
from the Modification of Diet in Renal Disease (MDRD) trial
showing that a rapid decline in GFR correlates directly with
proteinuria and is independent of diet or blood pressure control
[28]. That baseline proteinuria predicts ESRF also derives indi-
rectly from the analysis of the results of the Angiotensin-Convert-
ing-Enzyme Inhibition in Progressive Renal Insufficiency (AIPRI)
trial [29], the largest study ever performed on ACE inhibition
therapy in renal disease progression in humans. The above study
recruited patients with a variety of renal diseases, mainly non-
diabetic, the majority of whom, however, had no measurable
proteinuria. Predictably, only few patients reached the end point
of doubling of baseline serum creatinine or ESRF, compared to
the present series. This discrepancy reinforces the concept of a
relationship between baseline urinary protein excretion values
and subsequent progression to renal failure.
Other than predicting a faster progression of the nephropathy,
baseline urinary proteins can be used as a marker to identify
patients who may benefit most from putative renoprotective
Fig. 3. Rate of glomerular filtration rate
(GFR) decline per tertile of baseline urinary
protein excretion rate and mean arterial
pressure (MAP).
Fig. 4. Progression to end-stage renal failure
per tertile of baseline urinary protein excretion
rate and mean arterial pressure (MAP).
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treatments. In the MDRD trial, patients with higher baseline
proteinuria were those who had their rate of GFR decline more
remarkably decreased by tight blood pressure control [28]. Simi-
larly, in the Lewis trial [18], diabetics with more advanced
nephropathy, who conceivably had more severe proteinuria, were
those whose progression to ESRF was more effectively delayed by
ACE inhibition. In alignment with this are data of the AIPRI
study showing that in non-diabetic renal disease, virtually all of
the renoprotective effects of the ACE inhibitor Benazepril were
accounted for by its capability to decrease the risk of doubling
baseline serum creatinine concentration in patients with more
than 3 g urinary protein excretion rate per day. In the REIN study
[21], among patients with urinary protein excretion rate . 3 g/24
hr, the higher the level of baseline proteinuria, the greater the
beneficial effect of Ramipril both in slowing the GFR decline and
in reducing the risk of ESRF. Again, this effect seems to be
directly related to the capability of ACE inhibitors to decrease
trans-glomerular traffic of plasma proteins and their consequent
renal toxicity [11, 12, 16, 30–32].
In conclusion, the present study demonstrates that the urinary
protein excretion rate is the best baseline predictor of progression
of nondiabetic proteinuric nephropathies. However, arterial hy-
pertension may contribute to the acceleration of renal injury
associated with enhanced traffic of plasma proteins. Thus, antihy-
pertensives that most effectively limit urinary protein excretion at
comparable levels of blood pressure control are those that most
effectively slow disease progression and delay or prevent ESRF in
proteinuric chronic nephropathies.
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(statistician), A. Del Favero, G. Ideo, E. Geraci, and U. Loi
Investigators and Institutions belonging to the Gruppo Italiano
di Studi Epidemiologici in Nefrologia (GISEN)
M. Bracchi, E. Costantino, F. Scolari, and R. Maiorca (Spedali Civili,
Brescia); F. Cofano, G. Fellin, and G. D’Amico (Ospedale Provinciale S.
Carlo Borromeo, Milano); D. Dissegna, A. Brendolan, and G. La Greca
(Ospedale S. Bortolo, Vicenza); A. Feriozzi and E. Ancarani (Ospedale
Grande di Viterbo, Viterbo); E. Gandini, I. D’Amato, and A. Giangrande
(Ospedale Provinciale, Busto Arsizio); G. Garneri and F. Giacchino (Os-
pedale Civile, Ivrea); N. Giotta, G. Giannico, O. Vitale, C. Manno, and F.P.
Schena (Policlinico, Bari); A. Mazzi, A. Borghetti, and G. Garini (Istituto
di Clinica Medica e Nefrologia, Parma); L. Mosconi, R. Pisoni, and T.
Bertani (Ospedali Riuniti, Bergamo); R. Novelli, F. Scanferla, and G.
Bazzato (Ospedale Provinciale Umberto I, Mestre); E. Oliva and C. Zoccali
(Centro di Fisiologia Clinica del CNR, Reggio Calabria); F. Pieri, S. Sisca,
and Q. Maggiore (USL Zona 10H, Bagno a Ripoli); E. Pignone, R. Boero,
and G. Piccoli (Ospedale Zonale Giovanni Bosco, Torino); R. Piperno, A.
Rosati, and M. Salvadori (Ospedale Regionale “Careggi-Monna Tessa,”
Firenze).
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